Hyaluron, Inc. company specializes in aseptically filling syinges and vials with liquid and lyophilized (treated for preservation) products serving the medical and pharmaceutical markets. Hyaluron manufacturing facility can accomodate the needs of clients small and large, from pre-clincial batches to commercial scale development. Hyaluron's expertise also extends into scaling up formulations such as emulsions, viscous gels, suspensions, liposomes, and proteins which will eventually fill the vials and syringes of the company's clients. The company can fill about 150,000 syringes a day and 75,000 vials.

Prometheus company markets several drugs that treat gastrointestinal disorders, such as irritable bowel syndrome and ulcerative colitis. Its Entocort, which it co-promotes with AstraZeneca, is a steroid that reduces the bowel inflammation associated with Crohn's disease. Prometheus Laboratories markets its products mainly to US gastroenterologists. It also pairs its drug offerings with a diagnostic testing service that helps doctors differentiate between various gastrointestinal diseases and prescribe the right Prometheus remedy; it runs all of its tests at its San Diego lab facility. Prometheus company plans to conduct an IPO.

Idenix Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of drugs for the treatment of human viral and other infectious diseases in the United States and Europe. The company's primary product includes Tyzeka/Sebivo for the treatment of hepatitis B virus. It also develops IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI), for the treatment of human immunodeficiency virus (HIV)/ acquired immune deficiency syndrome (AIDS). In addition, Idenix Pharmaceuticals, Inc. focuses on the development of drugs for the treatment of hepatitis C virus. It has a license agreement with GlaxoSmithKline to develop, manufacture, and commercialize its NNRTI compounds, including IDX899 for the treatment of HIV/AIDS. The company was founded in 1998 and is headquartered in Cambridge, Massachusetts. Idenix Pharmaceuticals, Inc. is a subsidiary of Novartis Pharma AG.

Alexza Pharmaceuticals, Inc. was founded in 2000 and is based in Mountain View, California. Alexza Pharmaceuticals, Inc., a specialty pharmaceutical development stage company, focuses on the research, development, and commercialization of products for the acute treatment of central nervous system conditions. Its technology, Staccato system, vaporizes an excipient-free drug to form a condensation aerosol that allows for systemic drug delivery. The company has six product candidates in clinical development, including AZ-004 (Staccato loxapine) that completed Phase 3 clinical trial for the acute treatment of agitation in patients with schizophrenia or bipolar disorder; AZ-104 (Staccato loxapine), which completed Phase 2a clinical trial to treat patients suffering from acute migraine headaches; and AZ-001 (Staccato prochlorperazine) that completed Phase 2b clinical trials to treat patients suffering from acute migraine headaches.Alexza products in clinical development also include AZ-007 (Staccato zaleplon), which completed Phase 1 clinical trial for the treatment of insomnia in patients who have difficulty falling asleep, including patients who awake in the middle of the night and have difficulty falling back asleep; AZ-003 that completed Phase 1 clinical trial (Staccato fentanyl) for the treatment of patients with acute pain, including patients with breakthrough cancer pain and postoperative patients with acute pain episodes; and AZ-002 (Staccato alprazolam), which completed Phase 2a proof-of-concept clinical trial for the treatment of panic attacks. The company has a development agreement with Autoliv ASP, Inc. to develop heat packages to incorporate into the company's single dose drug delivery devices. It was formerly known as Alexza Molecular Delivery Corporation and changed its name to Alexza Pharmaceuticals, Inc. in July 2005.

Orexigen Therapeutics was founded in 2002 and is headquartered in La Jolla, California. Orexigen Therapeutics, Inc., a biopharmaceutical company, focusing on the development of pharmaceutical product candidates for the treatment of obesity. Orexigen Therapeutics's lead combination product candidates targeted for obesity are Contrave, which is in Phase III clinical trials, and Empatic, which is in the later stages of Phase II clinical development. It selected these two product candidates for obesity based research regarding CNS regulation of appetite and energy expenditure, as well as mechanisms in the brain that reinforce unhealthy eating behaviors. Each of these product candidates is a combination of generic drugs that is screened for synergistic CNS activity.

Essential Group, Inc. company was founded in 1994 and taken private in 2007. Essential Group (formerly AmericasDoctor) is helping medical researchers find a more advanced way to cure that bellyache. The company acts as a contract research organization (CRO) to handle everything needed in a clinical drug trial, including study design, patient recruitment, clinical monitoring, and writing up the findings. It conducts Phase I-IV trials in areas such as cardiology, gastroenterology, urology, and women's health through test sites across the US. Essential Group's primary clients are pharmaceutical and biotechnology companies.

Tongjitang Chinese Medicines Company was founded in 1995 and is headquartered in Shenzhen, the People's Republic of China. Tongjitang Chinese Medicines Company, through its subsidiaries, engages in the development, manufacture, marketing, and sale of Chinese medicines, nutritional products, and Tibetan recipe-originated plant-based medicines in the People’s Republic of China. The company also involves in the wholesale and retail of medicines. It offers Xianling Gubao for the treatment of osteoporosis, osteoarthritis, ischemic bone necrosis, and bone fractures; Zaoren Anshen Capsules for the treatment of insomnia; and moisturizing and anti-itching Capsules for the treatment of inflammatory skin conditions. The company also produces and sells Dianbaizhu Syrup for the treatment of vertigo; Compound Glycyrrhiza oral solution for the treatment of upper respiratory infections; Jiao Ti Guo Jiao Bi Capsules that prevent gastritis and ulcers; Bu Shen Yi Lao capsules, which improve memory, breathing, hearing, and general malaise; Xin Nao Kang capsules for the treatment of stroke and coronary artery disease; Jincishen Mixture used as an ancillary to treatment of cancer; Heiguteng capsules for the treatment of rheumatoid arthritis; Chongcao Qingfei capsules for the treatment of Chronic Obstructive Pulmonary Disease; Fengshi Gutong capsules for the treatment of rheumatoid arthritis; and Jingshu Granules for treatment of degenerative osteoarthritis. In addition, its product pipeline candidates comprise Jing Tong Ting, a phase III clinical trial product for menstrual pain; Da An Granules, a phase III ongoing product for anxiety; Yushuda Tablets, a phase III ongoing product for depression; and Dan Xian Kang Gu Capsules, a phase III design ongoing product for ischemic necrosis.

The National Institutes of Health (NIH), through its own research and the distribution of grants, seeks to understand disease inside and out. Part of the US Department of Health and Human Services, the NIH is the government's main medical research entity. It comprises 27 institutes and centers covering every medical discipline, from general medical sciences to alternative therapies. The organization has nearly 6,000 scientists of its own and gives out some 50,000 grants to researchers at more than 3,000 universities, hospitals, and research labs in all 50 states. Among its vast array of projects, NIH has supported efforts to develop an AIDS vaccine, map human genetic variation, and study avian flu.

Marker Gene Technologies sells itself. The company offers drug researchers a variety of marker genes for monitoring gene expression, intracellular targeting, and other purposes. The company's marker genes are used in research for agricultural biotechnology, cell culturing, and bacteriology. Additional products include reagents, enzyme substrates and kits, and other molecular biology products. Marker Gene Technologies also maintains four fully equipped laboratories from which it provides contract research services for biotechnology and pharmaceutical clients. The firm markets its products through a number of distributors in the US and abroad, in Europe, Asia, and the Middle East.

meros Corporation was founded in 1994 and is based in Seattle, Washington. Omeros Corporation is a clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. The Company’s clinically advanced product candidates are derived from its PharmacoSurgerytm platform designed to improve the clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Its PharmacoSurgery platform is based on low-dose combinations of therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to preemptively inhibit inflammation and other problems caused by surgical trauma and to provide clinical benefits both during and after surgery.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.